中文摘要：

目的分析慢性粒细胞白血病（CML）异基因造血干细胞移植（allo—HSCT）治疗的危险因素，以利于更好地规避移植风险。方法回顾性研究分析121例接受allo—HSCT的CML患者。预后评估参照EBMT积分，即Gratwoh]积分，危险因素包括供者来源、患者年龄、患者移植前疾病状态、供患者性别差异、疾病确诊至移植时间。将患者分为3组：低危组（0～2分）、中危组（3～4分）和高危组（5分）。结果所有患者allo—HSCT后中位随访时间为37（1～126）个月，预期5年总生存（OS）率、无复发死亡（NRM）率及复发（RR）率分别为（56．8±5．0）％、（35．6±4．9）％和（12．9±3．7）％。其中低危组患者分别为（66．0±6．1）％、（28．8±6．0）％和（7．84-3．3）％，明显优于中危组[（47．2±8．7）％、（43．6±8．5）％和（18．7±8．1）％]和高危组[（16．8±15．2）％、（66．7±25．5）％和（50．0±25．0）％]，差异具有统计学意义（P值分别为0．0015、0．045和0．0053）。结论EBMT危险因素积分系统能全面反映预测allo—HSCT治疗CML的疗效、复发率和移植相关死亡率。

英文摘要：

Objective To analyze the risk factors of allogeneic stem cell transplantation （alIo-SCT） for ehroninc myeloid leukemia （CML） in an attempt to avoid transplant risks. Methods A total of 121 CML patients received allo-SCT were analyzed retrospectively. The risk analysis was based on the EBMT score （ gratwohl score） which included donor type, age of patients, disease status before transplantation, donor/recipient sex match and time interval between diagnosis to alIo-SCT. Patients were divided into 3 risk groups based on their EBMT score： low risk （score 0 -2）, intermediate risk （3 -4） and high-risk （5）. Results The median follow-up duration was 37 （ 1 - 126） months. The estimated 5-year overall survival （5 y-OS）, non-relapse mortality （5 y-NRM） and relapse rate （5 y-RR） were （56.8 ±5.0）% , （35.6 ±4.9）% and （12.9±3.7）%, respectively. The5y-OS, NRM and RR were （66.0±6.1）%, （28.8±6.0）% and （7.8 ± 3.3 ） % in the low risk group being significantly superior to both intermediate-risk [ （47.2 ± 8.7 ） % , （43.6±8.5）% and （18.7 ±8. 1）%] and high-risk group [（16.8 ±15.2）%, （66.7 ±25.5）% and （50.0 ± 25.0） % ] （P = 0. 0015, 0.045 and 0.0053 for OS, NRM and RR respectively）. Conelusion The EBMT risk score can effectively predict the overall outcome, relapse and transplant-related mortality of allo-SCT for CML patients.